Business Description
Alkem Laboratories Ltd
ISIN : INE540L01014
Total Employee Number:
22,833Compare
Compare
Traded in other countries / regions
ALKEM.India Index Membership
NIFTY 500 IPO Date
2015-12-23Description
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.44 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | 0.6 | |||||
Interest Coverage | 16.32 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 7.85 | |||||
Beneish M-Score | -2.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.7 | |||||
3-Year EBITDA Growth Rate | 25.9 | |||||
3-Year EPS without NRI Growth Rate | 32.5 | |||||
3-Year FCF Growth Rate | -2.4 | |||||
3-Year Book Growth Rate | 15.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.15 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.99 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.82 | |||||
9-Day RSI | 57.75 | |||||
14-Day RSI | 58.29 | |||||
3-1 Month Momentum % | -1.24 | |||||
6-1 Month Momentum % | -9.13 | |||||
12-1 Month Momentum % | 9.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.55 | |||||
Quick Ratio | 1.86 | |||||
Cash Ratio | 1.04 | |||||
Days Inventory | 221.29 | |||||
Days Sales Outstanding | 70.6 | |||||
Days Payable | 142.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.92 | |||||
Dividend Payout Ratio | 0.25 | |||||
3-Year Dividend Growth Rate | 39 | |||||
Forward Dividend Yield % | 0.36 | |||||
5-Year Yield-on-Cost % | 1.69 | |||||
Shareholder Yield % | -0.24 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.38 | |||||
Operating Margin % | 17.83 | |||||
Net Margin % | 15.65 | |||||
EBITDA Margin % | 23.2 | |||||
FCF Margin % | 9.15 | |||||
OCF Margin % | 13.34 | |||||
ROE % | 17.64 | |||||
ROA % | 11.73 | |||||
ROIC % | 16.9 | |||||
3-Year ROIIC % | 44.93 | |||||
ROC (Joel Greenblatt) % | 44.55 | |||||
ROCE % | 20.11 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 29.1 | |||||
Forward PE Ratio | 28.31 | |||||
PE Ratio without NRI | 27.72 | |||||
Shiller PE Ratio | 40.95 | |||||
Price-to-Owner-Earnings | 33.45 | |||||
PEG Ratio | 2.57 | |||||
PS Ratio | 4.56 | |||||
PB Ratio | 4.84 | |||||
Price-to-Tangible-Book | 5.19 | |||||
Price-to-Free-Cash-Flow | 49.77 | |||||
Price-to-Operating-Cash-Flow | 34.12 | |||||
EV-to-EBIT | 21.3 | |||||
EV-to-EBITDA | 18.91 | |||||
EV-to-Forward-EBITDA | 18.42 | |||||
EV-to-Revenue | 4.39 | |||||
EV-to-Forward-Revenue | 3.71 | |||||
EV-to-FCF | 48.57 | |||||
Price-to-GF-Value | 0.92 | |||||
Price-to-Projected-FCF | 2.53 | |||||
Price-to-DCF (Earnings Based) | 1.73 | |||||
Price-to-DCF (FCF Based) | 4.43 | |||||
Price-to-Median-PS-Value | 1.17 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.23 | |||||
Price-to-Graham-Number | 2.53 | |||||
| Price-to-Net-Current-Asset-Value | 12.99 | |||||
Earnings Yield (Greenblatt) % | 4.7 | |||||
FCF Yield % | 2.02 | |||||
Forward Rate of Return (Yacktman) % | 12.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alkem Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 147,122.7 | ||
| EPS (TTM) (₹) | 192.51 | ||
| Beta | 0.8618 | ||
| 3-Year Sharpe Ratio | 0.46 | ||
| 3-Year Sortino Ratio | 0.94 | ||
| Volatility % | 10.54 | ||
| 14-Day RSI | 58.29 | ||
| 14-Day ATR (₹) | 117.54183 | ||
| 20-Day SMA (₹) | 5506.475 | ||
| 12-1 Month Momentum % | 9.45 | ||
| 52-Week Range (₹) | 4738.5 - 5933.5 | ||
| Shares Outstanding (Mil) | 119.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alkem Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alkem Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-13 16:30 | In 122 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 121 days | ||
| General meeting for 2026 | 2026-08-25 11:00 | In 42 days | ||
| First quarter earnings conference call for 2027 | 2026-08-12 16:30 | In 29 days | ||
| First quarter earnings results for 2027 | 2026-08-12 | In 28 days | ||
| INR 10.000000 Cash Dividend | 2026-08-07 | In 23 days | ||
| Annual report for 2026 | 2026-07-21 | In 6 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-28 16:30 | 5,451.50 (+0.68%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-28 | 5,451.50 (+0.68%) | ||
| INR 43.000000 Cash Dividend | 2026-02-20 | 5,377.00 (-2.54%) |
Show
Entries
Alkem Laboratories Ltd Frequently Asked Questions
What is Alkem Laboratories Ltd(NSE:ALKEM)'s stock price today?
The current price of NSE:ALKEM is ₹5601.50. The 52 week high of NSE:ALKEM is ₹5933.50 and 52 week low is ₹4738.50.
When is next earnings date of Alkem Laboratories Ltd(NSE:ALKEM)?
The next earnings date of Alkem Laboratories Ltd(NSE:ALKEM) is 2026-08-12 Est..
Does Alkem Laboratories Ltd(NSE:ALKEM) pay dividends? If so, how much?
The Dividend Yield %  of Alkem Laboratories Ltd(NSE:ALKEM) is 0.92% (As of Today), Highest Dividend Payout Ratio of Alkem Laboratories Ltd(NSE:ALKEM) was 0.31. The lowest was 0.08. And the median was 0.24. The  Forward Dividend Yield % of Alkem Laboratories Ltd(NSE:ALKEM) is 0.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Alkem Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers